US 7,579,316 B2
	Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
Sanjay D. Khare, Newbury Park, Calif. (US); and Ulrich Feige, Benglen (Switzerland)
Assigned to Amgen Inc., Thousand Oaks, Calif. (US)
Filed on Feb. 14, 2005, as Appl. No. 11/57,923.
Application 11/057923 is a continuation of application No. PCT/US2004/035415, filed on Oct. 26, 2004.
Claims priority of provisional application 60/515199, filed on Oct. 27, 2003.
Prior Publication US 2005/0287152 A1, Dec. 29, 2005
Int. Cl. A61K 38/16 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01)

U.S. Cl. 514—12  [514/21; 424/134.1; 530/350; 530/387.3]

21 Claims

1. A method of treating an immune reaction to an immunogenic therapeutic protein selected from the group consisting of a 30kDa TNF inhibitor, a 40kDa TNF inhibitor, and a peptide-Fc fusion molecule which binds to nerve growth factor, comprising administering a therapeutically effective amount of CTLA-4 comprising a polypeptide, selected from the group consisting of (a) SEQ ID NO: 1, (b) extracellular domain of CTLA-4, (c) residues 1-124 of SEQ ID NO:1, and (d) a variant of any of the CTLA-4 peptides (a)-(c) having a substitution of a different amino acid for Ser25, Ala29, Thr30, Leu104 and/or Gly105 relative to SEQ ID NO:1, to a subject before, during, and/or after administration of the immunogenic therapeutic protein, wherein administration of CTLA-4 decreases the incidence or intensity of an immune reaction caused by the immunogenic therapeutic protein in the subject.